Karyopharm Therapeutics Q4 2023 GAAP EPS $(0.36) Misses $(0.30) Estimate, Sales $33.75M Miss $35.40M Estimate
Karyopharm Therapeutics Q4 2023 GAAP EPS $(0.36) Misses $(0.30) Estimate, Sales $33.75M Miss $35.40M Estimate
Karyopharm Therapeutics 2023年第四季度GAAP每股收益（0.36）未達到預期（0.30）美元，銷售額爲3,375萬美元，低於3540萬美元的預期
Karyopharm Therapeutics (NASDAQ:KPTI) reported quarterly losses of $(0.36) per share which missed the analyst consensus estimate of $(0.30) by 20 percent. The company reported quarterly sales of $33.75 million which missed the analyst consensus estimate of $35.40 million by 4.68 percent. This is a 0.50 percent increase over sales of $33.58 million the same period last year.
Karyopharm Therapeutics（納斯達克股票代碼：KPTI）公佈的季度虧損爲每股0.36美元，比分析師普遍預期的0.30美元（0.30美元）低20％。該公司公佈的季度銷售額爲3,375萬美元，比分析師普遍預期的3540萬美元低4.68％。這比去年同期的3,358萬美元的銷售額增長了0.50％。